PMID- 28100544
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20181113
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 103
IP  - 8
DP  - 2017 Apr
TI  - Oscillatory whole-body vibration improves exercise capacity and physical
      performance in pulmonary arterial hypertension: a randomised clinical study.
PG  - 592-598
LID - 10.1136/heartjnl-2016-309852 [doi]
AB  - OBJECTIVE: In patients with pulmonary arterial hypertension (PAH), supportive
      therapies may be beneficial in addition to targeted medical treatment. Here, we
      evaluated the effectiveness and safety of oscillatory whole-body vibration (WBV) 
      in patients on stable PAH therapy. METHODS: Twenty-two patients with PAH (mean
      PAP>/=25 mm Hg and pulmonary arterial wedge pressure (PAWP)</=15 mm Hg) who were 
      in world health organization (WHO)-Functional Class II or III and on stable PAH
      therapy for>/=3 months, were randomised to receive WBV (16 sessions of 1-hour
      duration within 4 weeks) or to a control group, that subsequently received WBV.
      Follow-up measures included the 6-min walking distance (6MWD), cardiopulmonary
      exercise testing (CPET), echocardiography, muscle-power, and health-related
      quality of life (HRQoL; SF-36 and LPH questionnaires). RESULTS: When compared to 
      the control group, patients receiving WBV exhibited a significant improvement in 
      the primary endpoint, the 6MWD (+35.4+/-10.9 vs -4.4+/-7.6 m), resulting in a net
      benefit of 39.7+/-7.8 m (p=0.004). WBV was also associated with substantial
      improvements in CPET variables, muscle power, and HRQoL. The combined analysis of
      all patients (n=22) indicated significant net improvements versus baseline in the
      6MWD (+38.6 m), peakVO2 (+65.7 mL/min), anaerobic threshold (+40.9 mL VO2/min),
      muscle power (+4.4%), and HRQoL (SF-36 +9.7, LPH -11.5 points) (all p<0.05). WBV 
      was well tolerated in all patients, and no procedure-related severe adverse
      events (SAEs) occurred. CONCLUSIONS: WBV substantially improves exercise
      capacity, physical performance, and HRQoL in patients with PAH who are on stable 
      targeted therapy. This methodology may be utilised in structured training
      programmes, and may be feasible for continuous long-term physical exercise in
      these patients. TRIAL REGISTRATION NUMBER: NCT01763112; Results.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not
      already granted under a licence) please go to
      http://www.bmj.com/company/products-services/rights-and-licensing/.
FAU - Gerhardt, Felix
AU  - Gerhardt F
AD  - Klinik III fur Innere Medizin, Herzzentrum der Universitat zu Koln, Cologne,
      Germany.
FAU - Dumitrescu, Daniel
AU  - Dumitrescu D
AD  - Klinik III fur Innere Medizin, Herzzentrum der Universitat zu Koln, Cologne,
      Germany.
FAU - Gartner, Carina
AU  - Gartner C
AD  - Klinik III fur Innere Medizin, Herzzentrum der Universitat zu Koln, Cologne,
      Germany.
FAU - Beccard, Ralf
AU  - Beccard R
AD  - Klinik und Poliklinik fur Allgemeine Kinderheilkunde, Universitat zu Koln,
      Cologne, Germany.
FAU - Viethen, Thomas
AU  - Viethen T
AD  - Klinik III fur Innere Medizin, Herzzentrum der Universitat zu Koln, Cologne,
      Germany.
FAU - Kramer, Tilmann
AU  - Kramer T
AD  - Klinik III fur Innere Medizin, Herzzentrum der Universitat zu Koln, Cologne,
      Germany.
FAU - Baldus, Stephan
AU  - Baldus S
AD  - Klinik III fur Innere Medizin, Herzzentrum der Universitat zu Koln, Cologne,
      Germany.
AD  - Cologne Cardiovascular Research Center (CCRC), Heart Center at the University of 
      Cologne, Cologne, Germany.
FAU - Hellmich, Martin
AU  - Hellmich M
AD  - Institut fur Medizinische Statistik, Informatik und Epidemiologie, Universitat zu
      Koln, Cologne, Germany.
FAU - Schonau, Eckhard
AU  - Schonau E
AD  - Klinik und Poliklinik fur Allgemeine Kinderheilkunde, Universitat zu Koln,
      Cologne, Germany.
FAU - Rosenkranz, Stephan
AU  - Rosenkranz S
AD  - Klinik III fur Innere Medizin, Herzzentrum der Universitat zu Koln, Cologne,
      Germany.
AD  - Cologne Cardiovascular Research Center (CCRC), Heart Center at the University of 
      Cologne, Cologne, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT01763112
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20170118
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiorespiratory Fitness
MH  - Echocardiography
MH  - *Exercise Tolerance
MH  - Female
MH  - Germany
MH  - Health Status
MH  - Humans
MH  - Hypertension, Pulmonary/diagnosis/physiopathology/psychology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Muscle Strength
MH  - Oscillometry
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Pulmonary Artery/*physiopathology
MH  - *Pulmonary Wedge Pressure
MH  - Quality of Life
MH  - Recovery of Function
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vibration/*therapeutic use
MH  - Walk Test
PMC - PMC5529961
EDAT- 2017/01/20 06:00
MHDA- 2017/07/25 06:00
CRDT- 2017/01/20 06:00
PHST- 2016/04/20 00:00 [received]
PHST- 2016/09/23 00:00 [revised]
PHST- 2016/09/29 00:00 [accepted]
PHST- 2017/01/20 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
PHST- 2017/01/20 06:00 [entrez]
AID - heartjnl-2016-309852 [pii]
AID - 10.1136/heartjnl-2016-309852 [doi]
PST - ppublish
SO  - Heart. 2017 Apr;103(8):592-598. doi: 10.1136/heartjnl-2016-309852. Epub 2017 Jan 
      18.